{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:08:37Z","timestamp":1789726117751,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,18]],"date-time":"2027-09-18T00:00:00Z","timestamp":1821225600000},"content-version":"am","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Glaucoma"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ogla.2026.03.002","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T08:19:17Z","timestamp":1773130757000},"page":"537-542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse Events and Intraocular Pressure\u2013Lowering Effect of Topical 0.5% Apraclonidine in Childhood Glaucoma"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-375X","authenticated-orcid":false,"given":"Abdelrahman M.","family":"Elhusseiny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8016-2875","authenticated-orcid":false,"given":"Marie Michele","family":"Macaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8281-9268","authenticated-orcid":false,"given":"Amr K.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4827-5014","authenticated-orcid":false,"given":"Ta C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ogla.2026.03.002_bib1","doi-asserted-by":"crossref","first-page":"117.e1","DOI":"10.1016\/j.jaapos.2021.12.009","article-title":"Etiology and outcomes of childhood glaucoma at a tertiary referral center","volume":"26","author":"Tam","year":"2022","journal-title":"J AAPOS"},{"key":"10.1016\/j.ogla.2026.03.002_bib2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ajo.2024.11.020","article-title":"Treatment patterns of childhood glaucoma in the United States: analysis of IRIS registry (intelligent research in sight)","volume":"271","author":"Fujita","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2026.03.002_bib3","series-title":"Childhood Glaucoma: Current Trends and Future Prospects","first-page":"197","article-title":"Medical therapy of childhood glaucoma","author":"Wang","year":"2024"},{"key":"10.1016\/j.ogla.2026.03.002_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3928\/01913913-20090101-05","article-title":"The safety and efficacy of glaucoma medication in the pediatric population","volume":"46","author":"Coppens","year":"2009","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.ogla.2026.03.002_bib5","doi-asserted-by":"crossref","first-page":"300.e1","DOI":"10.1016\/j.jaapos.2022.08.526","article-title":"Topical netarsudil 0.02% as adjunctive therapy in refractory pediatric glaucoma","volume":"26","author":"Elhusseiny","year":"2022","journal-title":"J AAPOS"},{"key":"10.1016\/j.ogla.2026.03.002_bib6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1091-8531(98)90109-4","article-title":"Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma","volume":"2","author":"Portellos","year":"1998","journal-title":"J AAPOS"},{"issue":"Suppl 1","key":"10.1016\/j.ogla.2026.03.002_bib7","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0039-6257(96)82027-3","article-title":"Preclinical evaluation of brimonidine","volume":"41","author":"Burke","year":"1996","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ogla.2026.03.002_bib8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00002512-199812030-00005","article-title":"Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension","volume":"12","author":"Adkins","year":"1998","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ogla.2026.03.002_bib9","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0161-6420(88)33038-1","article-title":"Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145)","volume":"95","author":"Gharagozloo","year":"1988","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2026.03.002_bib10","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/archopht.1995.01100120044006","article-title":"Effects of brimonidine on aqueous humor dynamics in human eyes","volume":"113","author":"Toris","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ogla.2026.03.002_bib11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.exer.2011.04.002","article-title":"Update on the role of alpha-agonists in glaucoma management","volume":"93","author":"Arthur","year":"2011","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ogla.2026.03.002_bib12","first-page":"24","article-title":"Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children","volume":"18","author":"Bowman","year":"2004","journal-title":"Eye Lond Engl"},{"key":"10.1016\/j.ogla.2026.03.002_bib13","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association declaration of helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ogla.2026.03.002_bib14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/ICU.0000000000000516","article-title":"New classification system for pediatric glaucoma: implications for clinical care and a research registry","volume":"29","author":"Thau","year":"2018","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ogla.2026.03.002_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","article-title":"Comparative effectiveness of first-line medications for primary open-angle glaucoma","volume":"123","author":"Li","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2026.03.002_bib16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/IJG.0b013e31818624e5","article-title":"Exposure to topical apraclonidine in children with glaucoma","volume":"18","author":"Wright","year":"2009","journal-title":"J Glaucoma"},{"key":"10.1016\/j.ogla.2026.03.002_bib17","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ajo.2006.04.052","article-title":"Efficacy of apraclonidine 0.5% in the diagnosis of Horner syndrome in pediatric patients under low or high illumination","volume":"142","author":"Chen","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2026.03.002_bib18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/archopht.122.2.276","article-title":"The use of apraclonidine in the diagnosis of horner syndrome in pediatric patients","volume":"122","author":"Bacal","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ogla.2026.03.002_bib19","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/bjo.79.12.1098","article-title":"Long term effect of apraclonidine","volume":"79","author":"Araujo","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2026.03.002_bib20","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1517\/17425250802457609","article-title":"Efficacy, safety, and current applications of brimonidine","volume":"7","author":"Fudemberg","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ogla.2026.03.002_bib21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0002-9394(14)72655-8","article-title":"Short-term efficacy of Apraclonidine Hydrochloride added to maximum-tolerated medical therapy for glaucoma","volume":"120","author":"Robin","year":"1995","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2026.03.002_bib22","doi-asserted-by":"crossref","first-page":"336.e1","DOI":"10.1016\/j.jaapos.2021.07.011","article-title":"Safety of apraclonidine eye drops in diagnosis of Horner syndrome in an outpatient pediatric ophthalmology clinic","volume":"25","author":"Eldib","year":"2021","journal-title":"J AAPOS"},{"key":"10.1016\/j.ogla.2026.03.002_bib23","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jamaophthalmol.2025.4243","article-title":"Systemic toxicity with use of Apraclonidine ophthalmic drops in pediatric patients","volume":"143","author":"Gish","year":"2025","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology Glaucoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589419626000323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589419626000323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:39:09Z","timestamp":1789724349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589419626000323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2589419626000323"],"URL":"https:\/\/doi.org\/10.1016\/j.ogla.2026.03.002","relation":{},"ISSN":["2589-4196"],"issn-type":[{"value":"2589-4196","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse Events and Intraocular Pressure\u2013Lowering Effect of Topical 0.5% Apraclonidine in Childhood Glaucoma","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Glaucoma","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ogla.2026.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}